|
[1]ZHANG Y, QU CF, REN JS, et al.Prevalence and death dataset of liver cancer in China[J].Chin J Oncol, 2015, 37 (9) :705-720. (in Chinese) 张玥, 曲春枫, 任建松, 等.中国肝癌发病与死亡数据集[J].中华肿瘤杂志, 2015, 37 (9) :705-720.
|
|
[2]YUAN G, HAN T, LIU ZZ, et al.Compound radix sophorae flavescentis combined with ensure nutrition on malnutrition of advanced liver cancer[J].Chin J Med Offic, 2017, 45 (9) :891-893. (in Chinese) 袁钢, 韩涛, 刘中正, 等.苦参联合安素治疗晚期肝癌营养不良效果观察[J].临床军医杂志, 2017, 45 (9) :891-893.
|
|
[3]LIU XH, ZHAO YM, ZHAO XF, et al.Diagnostic and therapeutic progress on hepatocellular carcinoma[J/CD].Chin J Liver Dis:Electronic Edition, 2017, 9 (2) :20-25. (in Chinese) 刘秀红, 赵一鸣, 赵晓飞, 等.肝细胞癌诊断与治疗研究进展[J/CD].中国肝脏病杂志:电子版, 2017, 9 (2) :20-25.
|
|
[4]ZHANG CY, ZHAO XX, LU ZM, et al.Research advances in sorafenib-induced apoptotic signaling pathways in liver cancer cells[J].J Clin Hepatol, 2016, 32 (4) :816-820. (in Chinese) 张朝亚, 赵相轩, 卢再鸣, 等.索拉非尼诱导肝癌细胞凋亡信号通路的研究进展[J].临床肝胆病杂志, 2016, 32 (4) :816-820.
|
|
[5]SUN H, HAN WJ.Analysis of Sola Fini for primary liver cancer[J].Pract J Cancer, 2014, 29 (4) :442-444. (in Chinese) 孙恒, 韩文杰.索拉非尼对原发性肝癌患者疗效的研究分析[J].实用癌症杂志, 2014, 29 (4) :442-444.
|
|
[6]MA GA.Clinical effect of sorafenib in treatment of advanced hepatocellular carcinoma[J].J Clin Res, 2016, 33 (5) :986-988. (in Chinese) 马国安.索拉非尼治疗中晚期肝细胞癌的临床疗效分析[J].医学临床研究, 2016, 33 (5) :986-988.
|
|
[7]YU L, LIN LZ.Clinical effect of traditional Chinese medicine combined with sunitinib in treatment of advanced liver cancer:A case report[J].Chin J Integr Trad West Med, 2014, 34 (6) :758-759. (in Chinese) 余玲, 林丽珠.中医药联合舒尼替尼治疗晚期肝癌1例[J].中国中西医结合杂志, 2014, 34 (6) :758-759.
|
|
[8]YANG XN, WU YL.RECIST-New guidelines to evaluate the response to treatment in solid tumors[J].J Evid-based Med, 2004, 4 (2) :85-90. (in Chinese) 杨学宁, 吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学, 2004, 4 (2) :85-90.
|
|
[9]GU CY.New criteria for drug toxicity:National Cancer InstituteCommon Toxicity Criteria version 2.0[J].Progr Japanese Med, 2001, 22 (11) :483-486. (in Chinese) 谷昌彦.新的药物毒副反应判定标准:NCI——CTC2.0版本[J].日本医学介绍, 2001, 22 (11) :483-486.
|
|
[10]SHAO JS, LU HZ, ZHANG YX.Research advances in epidemiology of hepatocellular carcinoma[J].Chin Hepatol, 2011, 16 (6) :503-505. (in Chinese) 邵家胜, 卢洪洲, 张永信.肝细胞癌流行病学研究进展[J].肝脏, 2011, 16 (6) :503-505.
|
|
[11]WAN J, TANG CX, FENG B, et al.Expressions of Numb and VEGF in hepatocellular carcinoma and the clinical significance[J].Chin J Gen Sur, 2015, 24 (1) :39-44. (in Chinese) 万健, 唐才喜, 冯斌, 等.原发性肝癌中Numb和VEGF的表达及临床意义[J].中国普通外科杂志, 2015, 24 (1) :39-44.
|
|
[12]MA Q, XIE SL, WANG GY, et al.Influence of lentiviral-mediated P27RF-Rho gene silence in invasion of liver cancer cells[J].J Jilin Univ:Med Edit, 2016, 42 (2) :260-265. (in Chinese) 马强, 谢淑丽, 王广义, 等.慢病毒介导靶向P27RF-Rho基因沉默对肝癌细胞侵袭性的影响[J].吉林大学学报:医学版, 2016, 42 (2) :260-265.
|
|
[13]GUO ZY, HUANG FZ.Targeted therapy for hepatocellular carcinoma at intermediate and advanced stage:Difficulties and hope[J].Chin J Gen Surg, 2017, 26 (1) :109-115. (in Chinese) 郭之野, 黄飞舟.中晚期肝细胞肝癌的靶向治疗:困境与希望[J].中国普通外科杂志, 2017, 26 (1) :109-115.
|
|
[14]LI SJ, YANG ZB.Research advances in the role of Wnt/β-catenin signaling pathway-related molecules in targeted therapy for liver cancer[J].Shandong Med, 2016, 56 (10) :99-101. (in Chinese) 李圣杰, 杨之斌.Wnt/β-catenin信号通路相关分子在肝癌靶向治疗中的研究进展[J].山东医药, 2016, 56 (10) :99-101.
|
|
[15]SHAO P, TANG SH, LIN X, et al.Research advances in vectors used in targeted gene therapy for liver cancer[J].Proce Clin Med, 2015, 24 (3) :211-214. (in Chinese) 邵平, 汤诗杭, 林翔, 等.肝癌靶向基因治疗载体研究进展[J].临床医药实践, 2015, 24 (3) :211-214.
|
|
[16]CHEN C.Wnt/β-catenin and TGF-βsignaling pathways and targeted therapy for liver cancer[J].Acta Acad Med Xuzhou, 2015, 35 (1) :67-70. (in Chinese) 陈聪.Wnt/β-catenin及TGF-β信号通路与肝癌的靶向治疗[J].徐州医学院学报, 2015, 35 (1) :67-70.
|
|
[17]RINI BI, ESCUDIER B, TOMCZAK P, et al.Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS) :A randomised phase 3 trial[J].Lancet, 2016, 378 (9807) :1931-1939.
|
|
[18]YUAN HH, BAI YX, ZHANG TT, et al.Clinical observation on efficacy and adverse reactions of sorafenib in treating advanced hepatocellular carcinoma[J].China Oncol, 2012, 22 (1) :52-55. (in Chinese) 苑珩珩, 白玉贤, 张婷婷, 等.以索拉非尼为基础治疗晚期肝细胞癌的疗效和不良反应临床观察[J].中国癌症杂志, 2012, 22 (1) :52-55.
|
|
[19]ZHOU XP, ZHANG L.Progress in detection methods and clinical applications of serum alpha fetoprotein[J].Int Med China, 2015, 10 (2) :264-266. (in Chinese) 周晓萍, 张玲.血清甲胎蛋白检测方法及临床应用研究进展[J].内科, 2015, 10 (2) :264-266.
|
|
[20]UEDA T.Current status of molecular targeted therapy for hematologic malignancies:Introduction[J].Int J Clin Oncol, 2014, 19 (1) :1-2.
|
|
[21]Mc NAMARA MG, LE LW, HORGAN AM, et al.A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma[J].Cancer, 2015, 121 (10) :1620-1627.
|
|
[22]PARIKH ND, MARSHALL VD, SINGAL AG, et al.Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma:An analysis of the SEER-medicare database[J].Hepatology, 2017, 65 (1) :122-133.
|
|
[23]MIN D, BI J, LIU X, et al.Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a smallmolecule VEGFR-2 tyrosine kinase inhibitor apatinib:A case report[J].Medicine (Baltimore) , 2016, 95 (31) :e4368.
|
DownLoad: